



## **FINAL**

### **Catabasis Pharmaceuticals to Present CAT-2054, a Potential Treatment for Nonalcoholic Steatohepatitis (NASH) and Hypercholesterolemia, at the National Lipid Association 2016 Scientific Sessions**

**CAMBRIDGE, MA, May 16, 2016** – [Catabasis Pharmaceuticals, Inc.](#) (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present CAT-2054, a potential treatment for NASH and hypercholesterolemia, at the upcoming National Lipid Association 2016 Scientific Sessions held May 19 - 22, 2016, in New Orleans at the New Orleans Hyatt Regency Hotel.

Joanne Donovan, M.D., Ph.D., Chief Medical Officer of Catabasis, will present a poster titled “Phase 1 Multiple Ascending Dose Study of CAT-2054, a Novel Oral Sterol Regulatory Element Binding Protein Inhibitor.” The poster presentation will take place on Friday, May 20, 2016, from 9:25 a.m. - 10:25 a.m. and on Saturday, May 21, 2016, from 9:25 a.m. - 10:00 a.m. local time in the Poster Hall.

#### **About CAT-2054**

CAT-2054 is an oral small molecule with a novel mechanism of action being developed as a potential treatment of nonalcoholic steatohepatitis (NASH) and hypercholesterolemia. By inhibiting Sterol Regulatory Element-Binding Protein (SREBP), a master regulator of lipid metabolism in the body, CAT-2054 has the potential to significantly reduce LDL-C and liver fat; it may also have beneficial effects on other metabolic parameters such as triglycerides and glucose. This profile may differentiate CAT-2054 from currently approved therapies and others in development. We have shown in pre-clinical models of NASH that the CAT-2000 series significantly improves liver inflammation, fibrosis and steatosis. We have previously reported positive top-line Phase 1 data, including reductions in LDL-C. We are currently conducting a Phase 2a trial of CAT-2054 in addition to high intensity statin therapy in patients with hypercholesterolemia, which may help guide future clinical trials in NASH and hypercholesterolemia.

#### **About Catabasis**

At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. We have product candidates in both rare diseases and serious lipid disorders. Our SMART (Safely Metabolized And Rationally Targeted) linker drug discovery platform enables us to engineer molecules that simultaneously modulate multiple targets in a disease. We are applying our SMART linker platform to build an internal pipeline of product candidates for rare diseases and plan to pursue partnerships to develop additional product candidates. For more

information on the Company's drug discovery platform and pipeline of drug candidates, please visit [www.catabasis.com](http://www.catabasis.com).

###

Corporate and Media Contact

Andrea Matthews

Catabasis Pharmaceuticals, Inc.

T: (617) 349-1971

[amatthews@catabasis.com](mailto:amatthews@catabasis.com)